


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT

VOLUNTARY EXTENSION OF LOCK-UP UNDERTAKINGS GIVEN BY CEOS

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**InSilico Medicine**”) on a voluntary basis.

Reference is made to the prospectus of the Company dated December 18, 2025 (the “**Prospectus**”). Unless otherwise defined, terms used herein shall have the same meaning as defined in the Prospectus.

The Company has recently received undertakings (the “**Extension Undertakings**”) from Dr. Aleksandrs Zavoronkovs, the chairman of the Board, an executive Director, CEO, CBO and the single largest shareholder of the Company, and Dr. Feng Ren, an executive Director, CEO and CSO of the Company (collectively, the “**Relevant Shareholders**”), regarding the voluntary extension of the lock-up periods of all of their equity interests in the Company as of the date of this announcement, which include:

1. 42,583,500 shares directly held by Dr. Aleksandrs Zavoronkovs; and
2. 8,740,820 shares interested by Dr. Feng Ren, including (i) 475,400 shares held by Dr. Feng Ren through his wholly-owned company; (ii) 5,065,420 underlying shares to be subscribed upon full exercise of options granted under the Pre-IPO Equity Incentive Plans; and (iii) 3,200,000 underlying shares to be issued upon vesting of share awards granted under Pre-IPO Equity Incentive Plans;

(collectively, the “**Equity Interests**”).

Each of the Relevant Shareholders has entered into a lock-up undertaking pursuant to which he has agreed that, during the period commencing from the date of the Prospectus up to and including the date falling twelve (12) months after the Listing Date (the “**Original Lock-up Period**”), he will not, directly or indirectly, dispose of any shares of the Company held by him (for further details, please refer to the Prospectus). The Original Lock-up Period will expire on December 29, 2026.

Pursuant to the Extension Undertakings, as the Relevant Shareholders remain positive of the growth potential, core competitiveness and industry prospects of the Company from a long-term perspective, and to safeguard the stability of the share price of the Company and capital market confidence, as well as the legitimate rights and interests of the shareholders of the Company, particularly the minority shareholders, each of the Relevant Shareholders has undertaken to extend the Original Lock-up Period in respect of the Equity Interests for an additional six (6) months, up to and including June 29, 2027. During such extended lock-up period, the Relevant Shareholders will not, in any manner, directly or indirectly, dispose of or otherwise reduce their Equity Interests.

For the avoidance of doubt, the Extension Undertakings shall not restrict (i) any cashless exercise or cashless vesting under the Pre-IPO Equity Incentive Plans or the Post-IPO Equity Incentive Plans (if applicable), in case of which the total number of Equity Interests may be subject to deduction in accordance with applicable tax laws and regulations; and (ii) the disposal of any shares by proxy grantors who have granted proxy attached to their shares in favour of Dr. Aleksandrs Zavoronkovs pursuant to the Voting Proxy Arrangement as disclosed in the Prospectus.

The Company considers that not reducing the Equity Interests in the Company by the Relevant Shareholders will help to further promote the sustainable, steady and healthy development of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company’s shares.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, June 30, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive Directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive Directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive Directors.